SOLICITATION NOTICE
B -- analysis of single neucleotide polymorphisms (SNPs.)
- Notice Date
- 7/18/2012
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- 2625310
- Point of Contact
- Susan Nsangou, Phone: 3014432104
- E-Mail Address
-
nsangous@mail.nih.gov
(nsangous@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. National Institute on Drug Abuse, Office of Acquisitions- Neurosciences, Station Support/Simplified Acquisitions (NIDA), on behalf of the National Institute on Neurological Disorders and Stroke (NINDS), intends to negotiate on a sole source basis with Translational Genomics Research Institute (Tgen), Phoenix, AZ, for the analysis of single neucleotide polymorphisms (SNPs.) The NINDS is currently conducting research on up to 1000 patients who have been enrolled in and treated under a multi-center trial of combination therapy (MS-CombiRx) using two approved disease-modifying therapies. The goal is to identify biomarkers by single nucleotide polymorphism (SNP) haplotype determination and link these with clinical- and MRI phenotypes in a large cohort of relapsing-remitting (RR-) MS patients and to identify biomarkers that separate MS patients and healthy, matched controls. Tgen is able to analyze single nucleotide polymorphisms (SNPs) to identify disease-causing genes, associations, and DNA signatures, all of which have profound implications for detection, prognosis and therapeutic intervention. Tgen has successfully completed the first phase of this study and will begin the process of analyzing the observed SNP results in the context of the CombiRx clinical trial outcome results which have just been completed in May 2012. The period of performance is 12 months. The acquisition is being conducted under simplified acquisition using FAR 12 procedures and is exempt from the requirements of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number NOI2625310 may be submitted to the NIDA, Station Support/Simplified Acquisition Branch, 31 Center Drive, Bldg 31, Room 1B59, Bethesda, MD 20892-2080, and Attention: Susan A. Nsangou, Contracting Officer.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/2625310/listing.html)
- Place of Performance
- Address: Phoenix, Arizona, United States
- Record
- SN02807857-W 20120720/120719000423-e87db4a037149d1f9dab566dc26eb8d0 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |